Trial Profile
A Phase II Open-Label Study of Subcutaneous CPG ODN (PF03512676) in Combination With Trastuzumab in Patients With Metastatic Breast Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Agatolimod (Primary) ; Trastuzumab
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 13 Jan 2016 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 11 Jun 2013 Planned end date changed from 1 Jan 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 26 Feb 2009 Additional lead trial centre identified as reported by ClinicalTrials.gov, last updated 26-2-2009.